Correction: Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation (Hematology Reports, (2017) 10.4081/hr.2017.7083)

• Type of Material: Article
• Authors: Anand P. Jillella, Emory University; Martha Arellano, Emory University; Leonard Heffner Jr., Emory University; Manila Gaddh, Emory University; Amelia Langston, Emory University; Hanna Khoury, Emory University; Abhishek Mangaonkar, Augusta University; Vamsi Kota, Emory University
• Language: English
• Date: 2019-01-01
• Publisher: PAGEPress
• Publication Version: Final Published Version
• Copyright Statement: © 2019, Page Press Publications. All rights reserved.
• License: Creative Commons Attribution-NonCommercial 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.4081/hr.2019.8395
• Title of Journal or Parent Work: Hematology Reports
• Volume: 11
• Issue: 4
• Start Page: 98
• End Page: 98
• Keywords: promyelecytic leukemia; Jehovah Witness
• Research Categories: Health Sciences, Oncology

Abstract

Dr. Mangaonkar’s last name was mistakenly spelled in this article: DOI:10.4081/hr.2017.7083 Acute promyelocytic leukemia (APL) is a hyper-acute leukemia and presents with cytopenias and disseminated intravascular coagulation. Jehovah’s Witnesses with APL offer a unique challenge during induction by refusing transfusion and pose a difficult challenge in this curable disease. Our focus over the last 8 years has been decreasing early deaths in APL in both academic and community centers. As a result we have extensive experience in APL induction with a proven improvement in early deaths. Three patients with APL belonging to the Jehovah’s Witness congregation were treated in our practice and published literature in treating Witnesses with APL was reviewed. It is highly imperative to prevent induction mortality in this patient population. The goal of treatment among the Witnesses is to prevent death during induction and subsequently cure them. We discuss the management and proactive measures to prevent induction mortality in this most curable blood cancer.